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Activation of nuclear factor of activated T cells
(NFAT) is crucial for immune responses. IKKε is an
IkB kinase (IKK)-related kinase, and the function of
IKKε remains obscure in T cells, despite its abundant
expression. We report that IKKε inhibits NFAT ac-
tivation and T cell responses by promoting NFATc1
phosphorylation. During T cell activation, IKKε was
transiently activated to phosphorylate NFATc1.
Loss of IKKε elevated T cell antitumor and antiviral
immunity and, therefore, reduced tumor develop-
ment and persistent viral infection. IKKε was acti-
vated in CD8+ T cells of mice bearing melanoma or
persistently infected with a model herpesvirus.
These results collectively show that IKKε promotes
NFATc1 phosphorylation and inhibits T cell re-
sponses, identifying IKKε as a crucial negative regu-
lator of T cell activation and a potential target for
immunotherapy.INTRODUCTION
Nuclear factors of activated T cells (NFATs) were originally
identified as key regulators of T cell activation (M€uller and Rao,
2010). The NFAT family consists of five transcription factors
(NFATc1–NFATc4 and NFAT5) that share similar domain organi-
zation and structure. NFAT proteins contain an amino-terminal
transactivation domain, a regulatory domain, a DNA-binding
domain and a carboxyl-terminal domain that often harbors an
additional transactivation domain (Chuvpilo et al., 1999, 2002;
M€uller and Rao, 2010). The regulatory domain contains multiple
serine/threonine-rich motifs that can be phosphorylated by
various kinases, e.g., casein kinase 1 (CK1), glycogen synthase
kinase 3b (GSK3b), and the dual-specificity tyrosine-phosphory-
lation-regulated kinase (DYRK) (M€uller and Rao, 2010). In resting
cells, coordinated phosphorylation of NFAT by these kinases
inactivates and excludes NFAT from the nucleus. Upon T cellThis is an open access article under the CC BY-Nactivation, calcium influx activates numerous calcium-depen-
dent enzymes, including the calcineurin phosphatase that
dephosphorylates NFAT, which results in NFAT nuclear translo-
cation and activation. NFAT is critical for not only the activation of
T cells but also the function of other immune and non-immune
cells (Greenblatt et al., 2010; Zanoni et al., 2009). In addition,
NFAT plays essential roles in diverse fundamental biological
processes, ranging from development to stem cell maintenance
(Horsley et al., 2008; M€uller et al., 2009). Derailed NFAT activa-
tion, not surprisingly, has been associated with tumor develop-
ment and progression (Mancini and Toker, 2009). Therefore,
identifying NFAT kinase is crucial for understanding the precise
regulation of NFAT and the biological functions thereof.
IkB kinase (IKK) epsilon (IKKε), an inducible IKK-related kinase
by inflammatory stimuli (Shimada et al., 1999), was originally
discovered for its role in interferon production in response to viral
infection (Fitzgerald et al., 2003; Sharma et al., 2003). Later, it
was found to be dispensable for interferon production and
primarily responsible for interferon-mediated antiviral activity
via phosphorylating STAT (signal transducer and activator of
transcription) transcription factors (Tenoever et al., 2007). Addi-
tionally, IKKε was identified as a breast cancer oncogene in a
genome-wide screen and was later implicated in the develop-
ment of other human cancers (Boehm et al., 2007; Guo et al.,
2009). Much effort has been spent in identifying substrates of
IKKε to understand its roles in cell transformation (Hutti et al.,
2009; Shen et al., 2012; Xie et al., 2011). Notably, IKKε is
abundantly expressed in T cells and is postulated to activate
necrosis factor kB (NF-kB) downstream of T cell receptor
(TCR) (Peters et al., 2000). Recent studies also indicate that
IKKε is involved in interleukin (IL)-17-dependent signaling by
phosphorylating the adaptor protein Act1 (Bulek et al., 2011)
and contributes to the maintenance of Th17 cell through
phosphorylating GSK3a (Gulen et al., 2012). Nevertheless, it is
unclear how IKKε regulates T cell response in general, despite
its abundant expression.
We report that IKKε promoted NFATc1 phosphorylation at
multiple serine residues within the regulatory domain, which
inhibited NFATc1 activation and T cell immune response.
Mutation of these serine residues rendered NFATc1 resistanceCell Reports 16, 405–418, July 12, 2016 ª 2016 The Author(s). 405
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Loss of IKKε Reduces the Latent Infection of gHV68 and Boost Antiviral T Cell Immunity
Age- and gender-matched mice were infected with gHV68 via intranasal (A, 40 PFU) or intraperitoneal (B–J, 1 3 106 PFU) route.
(A) Viral lytic replication in the lung was determined by plaque assay at indicated days postinfection (dpi).
(B) Viral genome frequency at 42 dpi was determined by limiting-dilution PCR.
(legend continued on next page)
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to IKKε-mediated phosphorylation and inhibition. Knockdown of
IKKε elevated Jurkat T cell activation, while knockout of IKKε in
mouse boosted T cell immunity and reduced persistent viral
infection and tumor burden. Adoptive transfer and depletion
experiments indicate that the elevated T cell immunity in
IKKε-deficient mice resides in the CD8+ T cell compartment.
Our study reveals an unexpected function of IKKε, which acts
as a critical negative regulator of T-cell-mediated immunity,
possibly via phosphorylating NFAT transcription factors.
RESULTS
Loss of IKKε Reduces Herpesvirus Latent Infection
IKKε is implicated in regulating interferon response against RNA
virus infection (Tenoever et al., 2007). To investigate the roles of
IKKε in DNA virus infection, we infected wild-type (WT) and
IKKε-deficient mice with murine gamma herpesvirus 68
(gHV68), a model herpesvirus closely related to human Kapo-
si’s-sarcoma-associated herpesvirus (KSHV) and Epstein-Barr
virus (EBV). Viral replications in the lung at 7 and 13 days
post-infection (dpi) were similar (Figure 1A). At 10 dpi, the viral
titer was higher in Ikbke/mice, suggesting the antiviral activity
of IKKε against gHV68 at an early time point post-infection. A
hallmark of herpesviruses is their propensity to establish latent
infection. We further examined latent infection of gHV68 with
limiting-dilution PCR. At 42 dpi, we detected a viral genome in
1 out of 200 splenocytes of WT mice (Figure 1B). Remarkably,
loss of IKKε reduced viral genome frequency to 1 out of 10,000
splenocytes, a level equivalent to 2% of gHV68 latency in WT
mice (Figure 1B). These results indicate that loss of IKKε greatly
reduced viral latent infection.
Loss of IKKε Elevated the Antiviral Response of CD8+
T Cells
A common denominator in immunity against persistent viruses is
the T cell immune response. The dramatic reduction in gHV68
latent infection prompted us to delineate T cell response against
gHV68. gHV68 infection in mice leads to a transient lytic replica-
tion phase lasting about 13 days, followed by the establishment
of latent infection in lymphoid cells (e.g., B cells) (Doherty et al.,
2001). When we infected mice with gHV68 via intraperitoneal
injection, WT and Ikbke/ mice had similar levels of spleno-
megaly (Figure S1A). The T cell counts in Ikbke/ mice slightly
increased compared to those of Ikbke+/+ mice (Figure S1B).
Loss of IKKε resulted in a 2- to 3-fold increase in virus-specific(C) Representative tetramer staining (ORF61) at 13 dpi.
(D) Tetramer staining was performed at indicated dpi.
(E) Splenocytes were isolated from gHV68-infected Ikbke+/+ and Ikbke/ mic
determined by intracellular staining.
(F) Splenocytes labeled with CFSE were pulsed with or without viral peptide and
was quantified.
(G) Ikbke+/+ and Ikbke/mice were mock treated or depleted with anti-CD8 antib
frequency was determined as in (B).
(H and I) CD8+ splenocytes of Ikbke+/+ or Ikbke/ mice were transplanted into C
response and viral latent infection in the splenocytes were analyzed by tetramer
(J) Ikbke+/+ and Ikbke/CD8+ splenocytes were mixed and transferred into Rag-2
and analyzed for CD45.1 (Ikbke+/+) and CD45.2 (Ikbke/) within the CD8+ T cell
Error bars denote SD. *p < 0.05; **p < 0.01; ***p < 0.001.CD8+ T cells at 13 dpi (Figure 1C). When CD8+ T cell response
was examined over time, we found that virus-specific CD8+
T cells increased more rapidly in Ikbke/ mice than in WT
mice, from 6 to 10 dpi (Figure 1D). The difference peaked at 13
dpi, and the viral-specific CD8+ T cell number in Ikbke/ mice
was 3-fold that in WT mice (Figure S1C). More Ikbke/ CD8+
T cells produced interferon (IFN)-g compared to WT cells when
stimulated with viral peptide (Figure 1E). Spleen viral load
(genome copy number) was comparable in WT and Ikbke/
mice at 6 and 10 dpi, but the viral load in Ikbke/ mice was
50% of that in WT mice at 13 dpi (Figure S1D). Although the
overall spleen structure was similar between mock- and
gHV68-infected mice, germinal centers were expanded in the
virus-infected spleens of WT and Ikbke/ mice compared to
mock-infected spleens (Figure S1E). gHV68 infection in WT
and Ikbke/mice induced equivalent amounts of virus-specific
antibodies in sera (Figure S1F) and comparable levels of IL-6 and
CCL5 in spleen (Figure S1G). These results agree with previous
reports that IKKε is dispensable for cytokine production in
response to viral infection (Tenoever et al., 2007).
Next, we performed an in vivo killing assay to assess the
functionality of the increased CD8+ T cells in gHV68-infected
mice. We observed a 40% reduction of antigen-loaded target
cells in gHV68-infected WT mice. Remarkably, antigen-bearing
splenocytes decreased by 70% in gHV68-infected Ikbke/
mice, indicative of an increased cytotoxic lysis by CD8+ T cells
(Figures 1F and S1H). To determine the effectiveness of CD8+
T cells in reducing gHV68 latent infection, we depleted CD8+
T cells with specific antibody from 16 dpi (Figure S2A). The
depletion slightly increased viral genome frequency in the
splenocytes of WT mice, which is consistent with the role of
CD8+ T cells in controlling viral latent infection (Cardin et al.,
1996). Remarkably, depletion of CD8+ T cells in IKKε-deficient
mice completely restored the viral latent infection level to that
of WT mice treated with anti-CD8 antibody (Figure 1G). The
curves of gHV68 latent infection were identical in WT and
IKKε-deficient mice that were depleted of CD8+ T cells, indi-
cating that the elevated CD8+ T cell response in IKKε-deficient
mice is primarily responsible for the deficit of gHV68 latent
infection. These results collectively support the conclusion that
loss of IKKε increases CD8+ T cell response, which, in turn,
diminishes gHV68 latent infection.
To test whether IKKε has an intrinsic activity in CD8+ T cells,
we transferred equal numbers of WT or IKKε-deficient (CD45.2)
CD8+ T cells into immune-competent CD45.1 recipient mice,e at 13 dpi and stimulated with viral antigenic peptide (ORF61). IFN-g was
transferred into gHV68 infected Ikbke+/+ and Ikbke/mice. The specific killing
ody starting at 16 dpi. Splenocytes were harvested at 42 dpi, and viral genome
D45.1 immune-competent mice infected with gHV68 for 16 days. CD8+ T cell
staining (H) and limiting-dilution PCR (I), respectively.
/mice that were infected with gHV68. At 13 dpi, splenocytes were harvested
subset.
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Figure 2. Knockdown or Pharmacological Inhibition of IKKε Promotes T Cell Activation
(A) Jurkat T cells transduced with control shRNA (shCTL) or shRNA against IKKε (shIKKε) were treated with DMSO or PMA plus ionomycin for 3 hr. Total RNAwas
extracted and analyzed by microarray. Top differentially expressed genes were shown. Color intensity denotes log2 normalized raw data.
(legend continued on next page)
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and the mice were then infected with gHV68. We observed that
the virus-specific CD8+ T cell population in Ikbke/ mice was
approximately 3-fold that in Ikbke+/+ mice at 16 dpi (Figures 1H
and S2B). Moreover, gHV68 latent infection in mice that received
Ikbke/ CD8+ T cells was reduced by 60%–70%, compared to
that in mice that received Ikbke+/+ CD8+ T cells (Figure 1I). We
also transferred WT and Ikbke/ CD8+ T cells into Rag-2/
mice and examined T cell expansion after gHV68 infection. There
were two times as many Ikbke/ CD8+ T cells as WT CD8+
T cells at 13 dpi (Figures 1J and S2C). These results demonstrate
an intrinsic role of IKKε in CD8+ T cell activation and expansion.
Knockdown of IKKε Elevates T Cell Response
To explore how IKKε inhibits T cell activation, we analyzed the
gene expression profile of Jurkat T cells in which IKKε was
depleted with short hairpin RNA (shRNA). Treatment with PMA
and ionomycin upregulated the expression of a few hundred
genes in WT cells (GEO: GSE79074), among which the expres-
sion of 50 genes was further increased in IKKε-depleted cells
upon activation (Figure 2A). This notable class of genes that
were significantly upregulated by IKKε knockdown is composed
of chemokines and chemotaxis-associated factors that are regu-
lated by NFAT activation, including CCL3, IL-2, IL-8, XCL1, and
XCL2. This result suggests that IKKε may regulate NFAT tran-
scription factors in T cells.
Next, we examined the mRNA and protein expression of IL-2
as surrogates to monitor NFAT activation regulated by IKKε.
Two IKKε shRNAs increased IL-2 mRNA by factors of 7 and 3
(Figure 2B) and the percentage of IL-2-positive cells by 2- to
4-fold (Figures 2C, S3A, and S3B) in stimulated Jurkat T cells.
While the expression of WT IKKε had no detectable effect on
IL-2 mRNA and protein levels, the expression of the kinase-defi-
cient mutant IKKεK38A elevated IL-2 mRNA and protein by fac-
tors of 3.5 and 2, respectively (Figures S3C–S3E). These results
suggest that IKKεK38A has a dominant-negative effect on
endogenous IKKε to elevate NFAT activation. The lack of inhibi-
tion of IL-2 gene expression by exogenous IKKε suggests that
endogenous IKKε is sufficient to suppress NFAT activation.
Moreover, IL-2 mRNA of mouse primary Ikbke/ T cells was
3-fold that of WT T cells upon stimulation (Figure 2D). Given
that TBK-1 is closely related to IKKε, we knocked down TBK-1
in Jurkat T cells, with or without IKKε knockdown, and found
that TBK-1 knockdown had no significant effect on IL-2 expres-
sion (Figures S3F–S3I). These results suggest that TBK-1 is
dispensable in regulating NFAT upon T cell activation. A recent
study has identified amlexanox, a drug clinically prescribed to
treat oral ulcers, as a specific inhibitor of IKKε (Reilly et al.,
2013). Consistent with this, treatment with amlexanox increased
the percentage of IL-2-positive T cells in a dose-dependent
manner (Figure 2E). IL-2 expression in Jurkat T cells is highly(B and C) Jurkat T cells were transduced with lentiviral shRNA and whole-cell lys
reverse transcription qPCR (B, bottom). IL-2 protein expression was examined b
(D) Isolated mouse CD3+ primary T cells were stimulated with PMA and ionomyc
(E) Jurkat T cells were stimulated with PMA and ionomycin (Iono), with increasing c
(F) Jurkat T cells stably expressing NFATc1 were activated with PMA plus iono
analyzed by two-dimensional gel electrophoresis and immunoblotting.
Error bars denote SD.dependent on NFAT dephosphorylation and activation (Chow
et al., 1999). Thus, we examined the effect of amlexanox on
the dephosphorylation of NFATc1. Two-dimensional gel electro-
phoresis analysis demonstrated that, when IKKε was inhibited
with amlexanox, NFATc1 shifted toward the negatively charged
side in the first dimension and migrated faster in the second
dimension (Figure 2F), indicating reduced phosphorylation that
was recapitulated by treatment with alkaline phosphatase (Fig-
ure S3J). Thus, amlexanox treatment inhibits IKKε and reduces
NFATc1 phosphorylation, which may lead to increased T cell
activation. Collectively, these results indicate that IKKε is a key
negative regulator of NFAT activation and T cell response.
IKKε Inhibits NFAT Activation
Our previous studies showed that a viral G-protein-coupled re-
ceptor (vGPCR) can potently activate NFAT (Zhang et al.,
2015) (Figure S4A). Next, we used an NFAT reporter assay to
examine the effect of IKKε on vGPCR-induced NFAT activation.
IKKε expression reduced NFAT activation by vGPCR in a dose-
dependent manner (Figure S4B). To probe the point of inhibition
by IKKε, we overexpressed NFATc1 and calcineurin (CnA) to
activate NFAT. Strikingly, the expression of IKKε was sufficient
to diminish NFAT activation induced by both molecules (Figures
S4C and S4D). Moreover, IKKε was as potent as DYRK2 in di-
minishing NFAT activation induced by NFATc1 (Figure 3A).
IKKa and IKKb, however, only weakly inhibited CnA-induced
NFAT activation (Figures S4E and S4F), further prompting us to
focus on IKKε for its regulatory roles in NFAT activation. To
test whether the kinase activity of IKKε is required for its inhibi-
tion of NFAT activation, we examined the effect of IKKεK38A
on NFAT activation. IKKε, but not IKKεK38A, abolished CnA-
induced NFAT activation in a dose-dependent manner (Fig-
ure 3B). Similarly, IKKε abrogated the nuclear translocation of
EGFP-NFATc1 upon treatment with ionomycin, whereas
IKKεK38A had no detectable effect on NFATc1 nuclear translo-
cation (Figures 3C and 3D). Collectively, these results indicate
that IKKε potently inhibits NFAT activation in a kinase-dependent
manner.
IKKε Promotes NFATc1 Phosphorylation via Direct and
Indirect Mechanisms
Since NFAT activation is primarily enabled by dephosphorylation
(M€uller and Rao, 2010), and the kinase activity of IKKε is required
for its inhibition of NFAT activation, we reasoned that IKKε likely
phosphorylates NFAT. Expression of NFAT kinases often retards
NFAT migration as analyzed by electrophoresis. Indeed, exoge-
nously expressed IKKε resulted in a more slowly migrating spe-
cies of NFATc1 (Figure 4A). The expression of IKKa, IKKb, or
IKKεK38A failed to retard NFATc1 migration (Figures 4A and
S5A). Furthermore, purified IKKε, but not IKKεK38A, was ableates were analyzed by immunoblotting (B, top) and total RNA was analyzed by
y intracellular staining (C).
in and IL-2 mRNA level was analyzed by real-time q-PCR.
oncentrations of amlexanox (Amlex) and analyzed by IL-2 intracellular staining.
mycin without (DMSO) or with amlexanox (50 mM). Precipitated NFATc1 was
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Figure 3. IKKε Inhibits NFAT Activation in a
Kinase-Dependent Manner
(A) 293T cells were transfected with a NFAT re-
porter plasmid cocktail and plasmids containing
the indicated genes. NFAT activation was deter-
mined by luciferase assay. WCL, whole-cell lysate;
IB, immunoblotting.
(B) Reporter assay was performed as in (A), except
that increasing amounts of plasmid containing WT
IKKε or IKKεK38A were used.
(C and D) 293T cells were transfected with EGFP-
NFATc1 alone or together with IKKε or IKKεK38A.
Cells were treated with ionomycin (1 mM) for 1 hr.
NFATc1 subcellular localization was analyzed by
fluorescence microscopy. Representative images
were shown (C). Around 300 cells were counted for
nuclear NFATc1 localization, and percentage was
calculated (D).
Error bars denote SD.to phosphorylate the N-terminal regulatory domain (amino acids
[aa] 1–319) of NFATc1 in vitro (Figure 4B). Screening glutathione
S-transferase (GST) fusion proteins carrying known phosphory-
lation motifs, we found that IKKε efficiently phosphorylated the
SP3 motif and weakly phosphorylated the SP2 sequence but
not SP1, SRR1, SRR2, or KTS sequences (Figure S5B). Further
mutational analysis of SP2 and SP3 sequences identified two
serine residues, not those classical SP sequences, which served
as phospho-acceptors (Figure S5C). These two serine residues
are embedded in a conserved motif, SVTDD(/EE)SWLG (Fig-
ure S5D). An in vitro kinase assay indicated that the second
serine residuewas the primary phosphorylation site (Figure S5D).
Given the close proximity of these IKKε phosphorylation sites to
the SP sequences, we tested whether IKKε can prime the SP
sites for GSK3b-mediated phosphorylation. Pre-phosphoryla-
tion of SP2 and SP3 by PKA led to robust phosphorylation by
GSK3b, while IKKε failed to do so, indicating that IKKε cannot
prime NFAT for GSK3b-mediated phosphorylation of SP sites
(Figure S5E).
To delineate the IKKε phosphorylation sites within NFATc1, we
purified NFATc1 from 293T cells with or without IKKε expression410 Cell Reports 16, 405–418, July 12, 2016and analyzed serine/threonine phosphor-
ylation by mass spectrometry. We identi-
fied four principal phosphorylation sites,
in addition to the two serine residues in
the SP3 site, within the N-terminal regula-
tory domain (Figure 4C). S117 of the CnA-
docking site and two residues in the SP3
sequences are relatively conserved
among NFAT proteins (Figure S5F). Phos-
phorylation frequency of three sites (S117,
S151, and S324) was approximately
doubled by IKKε expression, whereas
that of S161 was increased from the basal
level of 13% to 76% with IKKε expres-
sion. S117 of the CnA-docking site was
shown to be phosphorylated by the Jun
N-terminal kinase (JNK), which reduced
the CnA-binding ability of NFATc1(Chow et al., 1997). Using an antibody specific for the phosphor-
ylated S117PRIEIT epitope, we found that exogenous IKKε
expression greatly elevated the phosphorylation of the CnA-
docking site (Figure 4D). Next, we tested whether IKKε can
directly phosphorylate these motifs in vitro. Except for the pep-
tide containing S117, the other peptides can be phosphorylated
by IKKε in vitro (Figures S5G and S5H). However, IKKε expres-
sion greatly increased the phosphorylation of the CnA-docking
peptide (S117) in transfected cells (Figure S5I). These findings
suggest that other kinases, such as the aforementioned JNK
(Chow et al., 1997), may relay signal transduction from IKKε to
NFAT by directly phosphorylating the CnA-docking site. We
also confirmed that the phosphorylation-mimetic mutation (S >
E) of the CnA-docking site diminished CnA binding by in vitro
GST pull-down (Figure S5J). These results collectively demon-
strate that IKKε promotes NFATc1 phosphorylation via direct
and indirect mechanisms.
To probe the functional consequence of these phosphoryla-
tion sites, we generated NFATc1 mutants carrying S > A muta-
tions. Reporter assays showed that a single S > A mutation of
four serines (S117, S151, S161, S324) within the N-terminal region
Figure 4. IKKε Phosphorylates NFATc1
(A) 293T cells were transfected with plasmids containing EGFP-NFATc1 and the indicated IKK. Whole-cell lysates (WCL) were analyzed by immunoblotting (IB)
with the indicated antibodies.
(B) In vitro kinase assay was performed using purified GST fusion proteins containing the N-terminal regulatory domain (1–319) of NFATc1. IKKε and IKKεK38A
were purified from 293T cells (silver staining), while GST and GST-NFATc1-N were purified from bacteria.
(C) Summary of the IKKε phosphorylation sites.
(D) 293T cells were transfected with plasmids containing the indicated genes. NFATc1 was precipitated with anti-FLAG antibody and, along with whole-cell
lysates (WCL), analyzed by immunoblotting.
(E) 293T cells were transfected with plasmids containing the indicated genes, and whole-cell lysates were analyzed by immunoblotting.
(legend continued on next page)
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conferred partial resistance to IKKε-mediated inhibition (Fig-
ure S5K). Mutations in the SP3 sequence had no apparent effect
on NFATc1-dependent gene expression (data not shown), sug-
gesting that these phosphorylations are involved in functions
other than transcription regulation of NFATc1. Alternatively,
these phosphorylations may be redundant with other phosphor-
ylations in regulating NFATc1-dependent gene expression.
Thus, we focused on the other four serines (S117, S151, S161,
and S324) for this study. When all four S > Amutations were intro-
duced into NFATc1, this mutant (designated NFATc1-4A) was
refractory to IKKε-mediated phosphorylation and inhibition (Fig-
ures 4E and 4F). By contrast, DYRK2 expression retarded the
migration of NFATc1-4A and WT NFATc1 to a similar degree
(Figure S5L). We noted that IKKε expression slightly retarded
the migration of NFATc1-4A, implying that other minor IKKε
phosphorylation sites exist in NFATc1. These results identified
major phosphorylation sites within the N-terminal regulatory
domain specifically impacted by IKKε. Next, we expressed
NFATc1-4A and WT NFATc1 in Jurkat T cells and determined
IL-2 protein expression. NFATc1-4A expression doubled the
percentage of IL-2-positive cells compared to WT NFATc1
upon stimulation, while NFATc1 and NFATc1-4A were equally
expressed in Jurkat cells (Figure 4G). Collectively, IKKε inhibits
NFAT activation through increasing NFATc1 phosphorylation.
IKKε Kinase Activity Is Coupled to T Cell Activation
The inhibition of NFAT by IKKεmay provide negative feedback to
T cell activation. We examined whether IKKε and NFATc1 co-
elute in lysates of resting and activated Jurkat T cells by gel filtra-
tion. In resting T cells, NFATc1 was primarily eluted in fractions
corresponding to protein sizes of 440–670 kDa, whereas IKKε
waswidely distributed in fractions corresponding to protein sizes
of 120–670 kDa, which demonstrated partly overlapped co-
elution (Figure 5A). NFATc1 was highly induced in activated
T cells and primarily co-eluted with IKKε in fractions corre-
sponding to protein sizes of 150–670 kDa. By contrast, IKKb
demonstrated a broader elution, with peak elution in fractions
corresponding to sizes >670 kDa in resting and activated Jurkat
T cells. Next, we monitored the activation of IKKε with an anti-
body specific for phosphorylated serine 172, a marker for acti-
vated IKKε, upon T cell activation. When T cells were stimulated
with antibodies against CD3 and CD28, IKKε activation was
detected as early as 10 min and lasted 30 min after stimulation
(Figure 5B). Similar kinetics of IKKε phosphorylation was also
observed when T cells were activated by PMA and ionomycin.
Despite the finding that knockdown of TBK-1 has no impact on
NFAT activation, we found that T cell activation by antibodies
against CD3 and CD28 also activated TBK-1 (Figure S6A). These
results indicate that T cell activation upregulates the kinase ac-
tivity of IKKε.
Six NFATc1 isoforms are generated in lymphocytes, and
they form three major bands in immunoblot analysis (Muham-
mad et al., 2014; Rudolf et al., 2014; Serfling et al., 2006).(F) NFAT activation in 293T cells by NFATc1-4A mutant was determined by lucife
(G) Jurkat T cells were infected with control lentivirus or lentivirus containing W
immunoblotting (top). After stimulation, the cells were analyzed by IL-2 intracellu
Error bars denote SD.
412 Cell Reports 16, 405–418, July 12, 2016Upon T cell activation, NFATc1 was quickly dephosphorylated
and then phosphorylated at around 60 min. In contrast,
NFATc1 was still partly dephosphorylated in IKKε-depleted
cells at 120 min post-stimulation (Figure 5C). Thus, IKKε con-
tributes to NFATc1 phosphorylation and potentially restricts its
rapid activation during T cell activation. Next, we developed
an antibody that specifically reacted with a peptide carrying
the phosphorylated serine 161 of NFATc1 (Figure S6B).
NFATc1 phosphorylation was detected at 10–30 min post-
stimulation, while NFATc1 phosphorylation was abolished in
Jurkat T cells in which IKKε was silenced (Figure 5C). To deter-
mine whether IKKε translocates into the nucleus where NFAT
export kinases exert their function, we performed fractionation
to obtain cytosolic and nuclear extract. Interestingly, IKKε
remained in the cytosolic fraction even when T cells were
activated (Figure S6C). IKKε was implicated in enabling the
activation of STAT and NF-kB transcription factors via direct
phosphorylation (Peters et al., 2000; Tenoever et al., 2007).
Thus, we determined the expression of two classic NF-kB-
dependent genes, A20 (TNFAIP1) and IkBa (NFKBIA), in Jurkat
T cells when IKKε was silenced. We found that knockdown of
IKKε had no apparent effect on the expression of A20 and
IkBa (Figure S6D). Furthermore, T cell activation did not
induce STAT1 phosphorylation as IFN-b treatment did (Fig-
ure S6E). These results show that IKKε depletion does not
impact NF-kB activation at early time points and that STAT1
is not phosphorylated at T708 in activated T cells.
To simultaneously probe the phosphorylation of multiple
sites in NFATc1 by IKKε during T cell activation, we estab-
lished a Jurkat T cell line stably expressing FLAG-NFATc1
and quantitatively analyzed purified NFATc1 with mass
spectrometry for phosphorylation. In resting T cells, the phos-
phorylated S161 can be detected at a low level, whereas phos-
phorylation of the other three sites was below detection
(Figure 5D). In activated T cells, the phosphorylation of S117,
S151, S161, and S324 increased significantly (Figure 5D). When
IKKε was inhibited with amlexanox in activated T cells, the
phosphorylation of all four sites decreased to the level below
detection (Figure 5D). This result demonstrates the critical
roles of IKKε in promoting the phosphorylation of all four sites
within NFATc1. Upon T cell activation, NFAT translocates into
the nucleus and binds to NFAT regulatory elements (promoters
and enhancers) to initiate gene transcription. Importantly, the
nuclear translocation of NFATc1 and NFATc2 was significantly
increased in activated T cells with IKKε knockdown (Figure 5E).
Furthermore, a chromatin immunoprecipitation (ChIP) assay
demonstrated higher binding of NFATc1 and NFATc2 to the
IL-2 promoter in IKKε knockdown T cells or IKKε-deficient
CD8+ T cells upon activation (Figures 5F and S6F). Using pu-
rified mouse CD8+ T cells, we showed that the kinase activity
of IKKε was increased in activated mouse T cells, and NFATc1
was phosphorylated by IKKε (Figure 5G). These results show
that IKKε restricts NFAT nuclear translocation during T cellrase assay.
T NFATc1 or NFATc1-4A mutant. NFATc1 was precipitated and analyzed by
lar staining (bottom).
Figure 5. T Cell Activation Upregulates the Kinase Activity of IKKε
(A) Jurkat T cells weremock treated or stimulated with PMA plus ionomycin for 1 hr. Cell extracts were analyzed by gel filtration chromatography with superose 6.
Fractions were analyzed by immunoblotting with indicated antibodies. V0, void volume. Numbers at the top indicate the size of protein complex in kilodaltons.
(B) Jurkat T cells were treated with antibodies against CD3 and CD28 (left panels) or PMA plus ionomycin. WCLs were analyzed by immunoblotting. WCL, whole-
cell lysate.
(C) Jurkat T cells expressing control shRNA or IKKε-shRNA were stimulated and analyzed by immunoblotting. P, phosphorylation.
(D) Jurkat T cells stably expressing FLAG-NFATc1 were stimulated with vehicle (DMSO) or ionomycin, with or without Amlexanox (50 mM) for 2 hr. NFATc1 was
affinity purified and analyzed by mass spectrometry for quantitative measurement of phosphorylation of peptides containing S117, S151, S161, and S324.
(E) Jurkat T cells were stimulated and fractionated into the cytoplasmic and nuclear fractions for immunoblotting analysis. P+I, PMA plus ionomycin.
(F) Jukat T cells were stimulated for 1 hr, and chromatin immunoprecipitation (ChIP) was performed using NFATc1 or NFATc2 antibodies. The enrichment of IL-2
promoter was determined by qPCR.
(G) Purified mouse CD8+ T cells were stimulated with PMA and ionomycin, and WCLs were analyzed by immunoblotting.
Error bars denote SD. *p < 0.05.
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Figure 6. Loss of IKKε Elevates T Cell
Antitumor Immunity and Reduces Tumor
Development
(A) Gender- and age (9- to 10-month-old)-matched
Ikbke+/+ and Ikbke/ mice were inoculated with
B16MO5cells via tail-vein injection.Mouse survival
was showed by Kaplan-Meyer survival curves.
(B–F) Gender- and age (10- to 12-week-old)-
matched Ikbke+/+ and Ikbke/ mice were inocu-
latedwithB16MO5cells via tail-vein injection.Mice
were euthanized at 32 days after inoculation.
Representative lungs were photographed (B) and
tumors were enumerated (C). The isolated lung
cells were analyzed by staining of CD8 (D), CD44
(E), and OVA tetramer (F).
Error bars denote SD. *p < 0.05; **p < 0.01; ***p <
0.001.activation. Taken together, T cell activation upregulates the
kinase activity of IKKε, which, in turn, phosphorylates NFAT,
providing a possible negative feedback to curtail T cell
activation.
Loss of IKKε Elevates T Cell Antitumor Immunity and
Reduces Tumor Development
Viral persistent infection is a physiological condition relevant to
the chronic development of cancers. The elevated CD8+ immu-
nity in Ikbke/ mice greatly reduced persistent viral infection,
and the elevated CD8+ T cell response can be beneficial in tumor
control. Thus, we determined whether IKKε-deficient mice are
more resistant to tumor development than WT mice, using
the B16 melanoma mouse model. While WT mice succumbed
to a lethal dose of B16 melanoma cells in an average of
16 days, the IKKε-deficient mice survived for an average of
29 days after inoculation of melanoma cells (Figure 6A).
IKKε-deficient mice harbored one-eighth as many tumors as
WT mice (Figures 6B and 6C). These results collectively
show that loss of IKKε renders mice more resistant to meta-
static melanoma development.
We determined CD8+ T cell immune response to MO5 mela-
noma cell, a B16-derived cell line that expresses thewell-defined414 Cell Reports 16, 405–418, July 12, 2016ovalbumin epitope SIINFEKL, which
readily enables the quantification of anti-
tumor T cell immune response. We found
that lungs of IKKε-deficient mice
harbored 4-fold as many CD8+ T cells as
those of WT mice (Figure 6D). A high level
of CD44 expression serves as a marker
for activated antitumor T cells (Okoye
et al., 2015). There were 0.3% and 2%
of CD44high T cells in the lungs of WT
and IKKε-deficient mice, respectively
(Figure 6E). Moreover, loss of IKKε also
increased OVA-specific CD8+ T cells in
the lung by more than 10-fold (Figure 6F).
The percentage of the CD44high popula-
tion of CD8+ T cells, however, only
marginally increased in IKKε-deficientmice, compared to WT mice (Figure S7A). The PD-1 expression
on CD8+ T cells was also marginally decreased in IKKε-deficient
mice (Figure S7B). These results collectively support the finding
that loss of IKKε results in elevated numbers of activated CD8+
T cells in the tumor microenvironment.
IKKε in CD8+ T Cells Is Activated in Mice Persistently
Infected with gHV68 or Bearing Chronic Tumor
Depletion of CD8+ T cells increased viral latent infection by less
than 2-fold in WT mice but more than 100-fold in IKKε-deficient
mice (Figure 1G). This result suggests that viral persistent
infection activates IKKε to suppress the antiviral immune
response of CD8+ T cells. To test this hypothesis, we isolated
T cells from mice latently infected with gHV68 and examined
IKKε activation and NFAT phosphorylation. Immunoblotting
analysis showed an increased NFATc1 phosphorylation (S161)
in CD8+ T cells of gHV68-infected mice, compared to those
of mock-infected mice (Figure 7A). Semiquantitative densitom-
etry analysis indicated that, in comparison to mock-infected
mice, there was a 4-fold increase of phosphorylated NFATc1
in gHV68-infected mice (Figure 7B). Consistent with this, we
observed a slight increase in IKKε protein expression and a
significant increase in S172-phosphorylated IKKε (Figures 7A
Figure 7. Chronic Activation of IKKε in Persistent Viral Infection and Tumor Development
Age- (12-week-old) and gender-matched mice were infected with gHV68 via intraperitoneal injection, the splenocytes were harvested, and CD8+ T cells were
purified.
(A) Whole-cell lysates (WCL) of CD8+ T cells were analyzed by immunoblotting with indicated antibodies.
(B and C) The relative levels of phosphorylated NFATc1 (B), IKKε, and phosphorylated IKKε (C) were determined by densitometry analysis.
(D) Age (12-week-old) and gender-matched mice were inoculated with B16 melanoma cells. Mice were euthanized at 28 dpi, lung CD8+ T cells were collected,
and whole-cell lysates were analyzed by immunoblotting.
Error bars denote SD. *p < 0.05; **p < 0.01.and 7C). We also examined NFATc1 phosphorylation in a B16
melanoma mouse model. When CD8+ T cells were isolated
from lungs of naive mice or mice inoculated with B16 mela-
noma cells, we observed significantly increased phosphoryla-
tion of NFATc1, an indicator of IKKε activation, in mice carrying
B16 melanoma cells (Figure 7D). No NFATc1 phosphorylation
was detected in CD8+ T cells from naive mice. Collectively,
these results support the finding that IKKε is activated in persis-
tent viral infection and tumor-bearing tissue/organs and that
activated IKKε phosphorylates NFATc1 to suppress CD8+
T cell immune response.DISCUSSION
T cells lie in the heart of host defense against chronic immune
challenge, such as persisting viral infection and cancer cells.
Cytotoxic CD8+ T cells can directly kill virus-infected or -trans-
formed cells, constituting a major arm of adaptive immunity.
Upon engagement of the TCRby antigenic peptide-loadedmajor
histocompatibility complex class I (MHC-I), T cells undergo rapid
activation and expansion. Central to T cell expansion and
ensuing response is the activation of NFAT transcription factors
and the expression of genes downstream of NFAT proteinsCell Reports 16, 405–418, July 12, 2016 415
(M€uller and Rao, 2010). Optimal T cell clonal expansion requires
an additional co-stimulatory signal from CD28 that is activated
by B7 family members (Chen and Flies, 2013). To date, a num-
ber of negative regulators are reported to hold T cell activation
in check, including NFAT kinases and surface checkpoint
molecules, e.g., CTLA-4 and PD-1 (Gibson et al., 2007; Oes-
treich et al., 2008). Several NFAT kinases, such as GSK3b,
casein kinases, and DYRK, can phosphorylate NFAT and
inhibit NFAT activation. Although biochemical data established
the inhibition of NFAT by these kinases, their roles in T cell
activation in vivo remain enigmatic. Interestingly, IL-7-depen-
dent activation of Jak3 in CD4CD8 double-negative thymo-
cytes was shown to phosphorylate NFATc1 and lead to its
nuclear translocation and activation, which is critical for the
survival and differentiation of early thymocytes (Patra et al.,
2013). IKKε is abundantly expressed in T cells, and its function
is not well understood. We report here that IKKε phosphory-
lates NFATc1 within its N-terminal regulatory domain and
inhibits NFAT activation. Upon T cell activation by TCR
engagement or calcium influx, IKKε is quickly activated within
10 to 30 min post-stimulation, which is in accordance with a
previous report (Peters et al., 2000). Phosphorylation of the
Ser161 of NFATc1 by IKKε replicates the activation kinetics of
IKKε, classifying IKKε as a negative-feedback kinase acting
immediately after T cell activation and differentiating IKKε
from other NFAT kinases.
Although similar activation kinetics was observed for TBK-1
during T cell activation, knockdown of TBK-1 had no detect-
able effect on IL-2 expression, even when IKKε expression
was depleted. Thus, the closely related TBK-1 and IKKε may
have distinct functions in T cells. TBK-1, but not IKKε, was
recently shown to modulate neuro-inflammation in CD4+
T cells via the AKT-mTORC1 (mammalian target of rapamycin
complex 1) signaling pathway (Yu et al., 2015). Our study indi-
cates that the major inhibitory role of IKKε resides in the CD8+
T cell compartment. Interestingly, the antibody against gHV68
was not affected by knockout of IKKε, suggesting that the
overall function of CD4+ T cells is not altered. These results
imply that TBK-1 and IKKε may act chiefly in CD4+ and CD8+
T cells, respectively. Alternatively, IKKε and TBK-1 may play
key roles in distinct signaling pathways, e.g., IKKε in NFAT
and TBK-1 in AKT pathway. Nevertheless, it remains unknown
how IKKε is activated during T cell activation. A recent study
reveals that free K48-linked polyubiquitin chains, catalyzed
by TRIM6, activate IKKε via promoting oligomerization (Rajs-
baum et al., 2014). Whether a similar mechanism of IKKε
activation is operating in T cells remains to be determined.
The mechanism of IKKε activation, in particular, and its roles
in innate immune signaling, in general, in T cells call for
investigation.
We provide substantial evidence that IKKε can function as a
negative-feedback NFATc1 kinase and restrict T cell activation.
IKKε-deficient mice generate a larger number of antiviral and
antitumor CD8+ effector T cells in vivo. It is noteworthy that
NFAT promotes anergy and exhaustion of activated CD8+
T cells if not partnered with other transcription factors (e.g.,
AP-1) (Martinez et al., 2015). Conceivably, depletion of IKKε
may elevate these signaling events to promote CD8+ T cell416 Cell Reports 16, 405–418, July 12, 2016activation rather than exhaustion. On the other hand, gHV68
infection and melanoma cells appear to explore the activation
of IKKε to restrict antiviral and antitumor CD8+ T cell response.
Similarly, the CD8+ T cell is crucial to control other persistent in-
fectious pathogens, including simian immunodeficiency virus
(SIV) infection in rhesus monkey (Schmitz et al., 1999) and hepa-
titis C virus (HCV) infection in human (Bowen and Walker, 2005;
Jo et al., 2009). These results agree well with the established
cytotoxic T lymphocyte (CTL) immunity in restricting persistent
pathogen infection and chronic cancer development. Despite
the robust phenotype of CD8+ T cell depletion, these findings
implicate the importance of the helper function of CD4+ T cells
in mounting proper immune response. Previous studies have
characterized roles of CD8+ and CD4+ T cells in EBV- and
KSHV-infected patients and in model systems ex vivo (Hislop
et al., 2005; Myoung and Ganem, 2011). Conceivably, CD4+
T cells are required to activateCD8+T cells that recognize diverse
murine gHV68 antigens. Lack of CD4+ T cell, as expected, re-
sulted inprogressive lossofCD8+Tcell function anduncontrolled
gHV68 replication (Cardin et al., 1996).
Overall, IKKε promotes NFATc1 phosphorylation during T cell
activation, and loss of IKKε robustly elevated the antiviral and
antitumor immunity in mice, suggesting that IKKε is a potential
immunotherapy target to fight chronic viral infection and
cancer.
EXPERIMENTAL PROCEDURES
Viruses, Mice, and Viral Infections
gHV68 was propagated in BHK21 cells as described previously (Feng et al.,
2008). IKKε knockout mice (Tenoever et al., 2007), CD45.1 mice, and RAG-2
knockout mice were purchased from Jackson Laboratory. Eight- to 10-week
old, gender-matched mice were used for all experiments, unless specified
otherwise. All animal work was performed under strict accordance with
the recommendations in the Guide for the Care and Use of Laboratory An-
imals of the NIH. The protocol was approved by the Institutional Animal Care
and Use Committee (IACUC) of the University of Southern California. For
gHV68 infection, mice were infected with the indicated infectious units of vi-
rus in 150 ml of PBS via intranasal or intraperitoneal injection.CD8+ T Cell Depletion
Gender- and age-matched Ikbke+/+ and Ikbke/ mice were intraperito-
neally (i.p.) infected with 1 3 106 plaque-forming units (PFUs) of gHV68.
Mice were mock treated or injected i.p. with purified anti-CD8 antibody
(1 mg) (Bio X Cell) at 16 dpi. The depletion was maintained by injecting
1 mg of anti-CD8 antibody every week. Splenocytes were harvested at
42 dpi, and viral genome frequency was determined by limiting-dilution
PCR.
Tetramer Staining
gHV68-infected mice were sacrificed at 6, 10, 13, and 42 days post-infection
(dpi), and the spleen was collected. Single-cell suspension was generated by
passing through a 40-mmstrainer on ice. Red blood cells (RBCs) were removed
by adding 5 ml of BD Pharm Lyse buffer (BD Biosciences). Cells were washed
once with cold PBS plus 1% fetal bovine serum (FBS) and subjected to
tetramer staining.
Tetramer staining was carried out as previously described (Molloy et al.,
2011). Briefly, cells were incubated with anti-CD16/32 antibody for 10 min
on ice, followed by staining for 1 hr in the dark with tetramers. Then, cells
were then stained with anti-CD8 antibody for 20 min on ice. Samples were
analyzed by flow cytometry using FACSCalibur, and data were analyzed
with FlowJo software.
Limiting-Dilution Nested PCR Detection of gHV68 Genome-Positive
Cells
The frequency of splenocytes harboring gHV68 genome was measured by
limiting-dilution PCR as previously described (Dong et al., 2010). Briefly,
mouse spleens were homogenized, re-suspended in isotonic buffer, and
subjected to 3-fold serial dilutions (from 104 to 41 cells per well) in a back-
ground of uninfected RAW 264.7 cells, with a total of 104 cells per well. Twelve
replicates were plated for each cell dilution. After being plated, cells were
subjected to lysis by proteinase K at 56C for 8 hr. Following inactivation of
the enzyme at 85C for 30 min, samples were subjected to nested PCR using
primers specific for gHV68 ORF72. Reaction products were separated using
2.5% UltraPure agarose (Invitrogen) gels and visualized by ethidium bromide
staining.
T Cell Adoptive Transfer
T cells of WT (CD45.1) and IKKε-deficient (CD45.2) mice were purified with a
CD8+ T cell isolation kit (Miltenyi Biotec). Two million T cells were combined
and transferred intravenously (i.v.) into RAG2-deficient mice. At 16 hr after
adoptive transfer, RAG2-deficient mice were infected with 106 PFU of
gHV68. Splenocytes were collected at 13 dpi and analyzed by flow cytometry
with antibodies against CD8, CD45.1, and CD45.2.
T cells from IKKε-deficient (CD45.2) mice were purified with a CD8+ T cell
isolation kit (Miltenyi Biotec), and 3 million of the purified CD8+ T cells were
injected i.v. into WT mice (CD45.1). Mice were then challenged with 106 PFU
of gHV68 (i.p.). Mice were euthanized at 16 dpi, and splenocytes were
collected and analyzed by flow cytometry with antibodies against CD8,
CD45.1, CD45.2, and virus-specific tetramer.
Melanoma Development in Mice
Mice were injected i.v. with B16.MO5 (MO5) melanoma cells expressing the
ovalbumin (OVA) antigen (2 3 105) and euthanized at the indicated time.
Melanoma tumors in the lung were enumerated. The entire lung was minced
and digested with collagenase. T cells were analyzed by flow cytometry with
antibodies against CD8, CD44, PD-1, and OVA tetramer (SIINFEKL).
Statistical Analysis
Data represent the mean of three independent experiments, and error bars
denote SD unless specified otherwise. A two-tailed Student’s t test was
used for statistical analysis. The mouse Kaplan-Meier survival curve was
generated using GraphPad 5, and the log-rank test applied to the mouse
survival data was also performed in GraphPad 5.
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